MedTrace Logo

Augmentation Study of Levetiracetam in Obsessive Compulsive Disorder

NCT00299611 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2013-04-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effectiveness of Levetiracetam augmentation relative to Placebo in SSRI non-remitters with obsessive compulsive disorder. The hypothesis is that anxiolytic effect of Levetiracetam is more beneficial when adding with a SSRI.

Conditions

  • Obsessive-Compulsive Disorder

Interventions

DRUG

Sertraline

Tablets, 50mg each, (1-3TABLETS/DAY) during the Open-label phase for first 8 wks.

DRUG

Levetiracetam

Tablets, dosage 500mg each tablet (1-4tablets/day)for 8 wks during the 2nd phase of the study.

DRUG

Placebo

Tablets, No active ingredient, (1-4tablets/day) for 8 wks during the 2nd phase of the study.

Sponsors & Collaborators

Principal Investigators

  • Wei Zhang, MD, PhD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2007-12-31
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00299611 on ClinicalTrials.gov